Analyst: FTC Unlikely to Force Teva, Ivax to Sell Off Many Assets for Merger

Drug Industry Daily
KEYWORDS Deals / FTC / generic
A A

Teva Pharmaceutical and Ivax will probably not have to sell off many products to consummate their pending merger, a Standard & Poor’s analyst said, despite an FTC request for more information about the proposed deal.

To View This Article:

Login

Subscribe To Drug Industry Daily